Navigation Links
Frost & Sullivan Examines the Key Challenges in the European Non-Invasive Ventilation Market
Date:7/21/2009

LONDON, July 21 /PRNewswire/ -- Europe's aging population has led to a rise in the number of registrations and diagnoses of respiratory diseases. While there has been a shift towards non-invasive ventilation to manage these diseases, manufacturers are struggling to maintain profit margins in this highly price sensitive market, while providing technologically advanced products at the same time.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

To provide decision makers with key insights into the European non-invasive ventilation market, the Healthcare Group at Frost & Sullivan will be hosting an online analyst briefing presentation on Wednesday 29 July 2009, at 4 p.m. BST. The briefing will benefit manufacturers and distributors of non-invasive ventilation devices and accessories in Europe.

"The quality of service and after-sales support provided by the manufacturer is an important criterion for the end-user, when it comes to making a choice between different ventilator manufacturers," says Frost & Sullivan Research Analyst Akanksha Joshi. "Manufacturers who offer bundling and flexible service contracts will therefore have an edge over their competitors."

To participate in this briefing, please email Patrick Cairns at patrick.cairns@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. Upon receipt of the above information, a registration link will be emailed to you.

About Frost & Sullivan:

Frost & Sullivan, the Growth Partnership Company, partners with clients
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Growth in African Medical Imaging Markets: Frost & Sullivan Examines the Potential
2. Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders, Advises Frost & Sullivan
3. Frost & Sullivan Lauds Marigot Ltd. and GTC Nutrition for Their Innovative CalciLife(TM)
4. Frost & Sullivan Identifies Innovative and Cost-Effective Technology as Key Competitive Factor in European Medical Device Market
5. Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies
6. APAC Sensors Market Likely to be Driven by Medical and Process Industries in 2009, Says Frost & Sullivan
7. Multiple Advantages to Boost Deployment of Wireless and Handheld Devices in Healthcare, States Frost & Sullivan
8. Frost & Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon
9. Cellular Technology Extends the Boundaries of E-healthcare, Says Frost & Sullivan
10. Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market, States Frost & Sullivan
11. Hospital Information Systems (HIS) Markets in Europe: Frost & Sullivan Reveals the Cost, Crunch and the Care Value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...developed a way to produce blood vessels by engine... Researchers at the University at Buffalo D...y that the bone marrow is an excellent source of a... applications. According to Dr. Stelios T....
...e University of Nottingham are amassing an arsenal... against the most deadly of hospital superbugs . .... Its defences are so strong it can resist most an...hcare Associated Infections (CHAI), with Dr Peter ...
...niversity researcher is experimenting with ways to...hat we like about our favourite snacks . S...nce and industry at K-State's College of Agricultu... this process can be used to make fibre-enriched f...
...found that women are the real bosses at home . ...s, wives have greater power in marriage problem-so... 72 married couples from Iowa, found that wives, o... not considering who raised the topic. As...
...ting dads will be given some tips on how to raise ... The British government is hoping that its 23milli...et technology to support parents will appeal to fa...w initiative, "Parent Know-How", parents will be a...
...ho killed his 25-year-old female neighbor was sent...of Alicia Ross by her neighbor Daniel Sylvester w...ousness, by an Ontario Superior Court judge who im...er in the death of Alicia Ross, intended to kill h...
Other Medicine News:Health News:New Blood Vessels can Be Created from Bone Marrow Stem Cells: Study 2Health News:The Hospital Superbugs 2Health News:The Hospital Superbugs 3Health News:Now, Fibre-enriched Tasty Snacks in the Making 2Health News:Women are the Real Bosses at Home 2Health News:Women are the Real Bosses at Home 3Health News:A Savage Murderer in Canada Gets Sentenced to Life 2
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC ), today announced the initial development and successful testing of a novel integra
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Omega 3 fatty acids appear to impact AMD progression 8896 1Omega 3 fatty acids appear to impact AMD progression 8896 2Omega 3 fatty acids appear to impact AMD progression 8896 3The Leukemia 26 Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 49377 1The Leukemia 26 Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 49377 2Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 1Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 2Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 3
... SUNNYVALE, Calif., April 13 Pharmacyclics, In...egun treating patients in a Phase,1 dose-escalatio... PCI-32765,an orally available, selective inhibito...al treatment for patients with relapsed or refract... the first Btk selective inhibitor to,be tested in...
... NOVATO, Calif., April 13 Raptor Pharmaceuticals ...ard: RPTP) today announced the appointment of Patr...r ("CMO"). Dr. Rioux will be responsible for the c...nical-stage drug development programs. , , (Logo:...YM074LOGO ) , , Raptor,s clinical programs inc...
Other Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 2Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 3Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 4Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 5
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
Medicine Products: